Omeprazole

Drug Profile

Omeprazole

Alternative Names: Antra; Belmazol; Losec; Mopral; Nuclosina; Omepral; Omeprazole magnesium; Omeprazon; Prilosec; Ulzol

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Hassle Lakemedel; Mitsubishi Tanabe Pharma Corporation
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 04 Feb 2016 No recent reports on development identified - Registered for Gastritis in Japan (PO)
  • 30 Jun 2014 Omeprazole is no longer licensed to Merck & Co in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top